Inducen-LD/RF

INPT for Lyme Disease & Relapsing Fever

Induced Native Phage Therapy (INPT) is being heralded by leading physicians and Ph.D. scientists as a “Nobel-prize worthy innovation” and a “profound paradigm shift in the treatment of infections.” This patent-pending technology is the scientific engine behind the Inducen product line, including Inducen-LD/RF—a formula developed specifically to support patients with Lyme disease, relapsing fever, and associated coinfections.

Through Biospectral Emission Sequencing™, this formulation delivers precise electromagnetic signatures designed to activate microbe-specific native phages—naturally occurring phages believed to have entered the body alongside the infection.

By supporting the body’s ability to epigenetically shift these phages from lysogenic to lytic states, Inducen-LD/RF helps promote the body’s own rapid and precise elimination of Borrelia, Bartonella, Babesia, and a broad range of stealth pathogens.

Place Your Order

To begin offering Inducen-LD/RF in your clinic:

Backed by Science

In a peer-reviewed clinical review, 26 patients with antibiotic-resistant Lyme disease underwent INPT treatment over just four days. Outcomes included:

  • 77% tested negative for Borrelia using the Phelix Borrelia Phage Test (92% sensitivity, 100% specificity) after 4 days.

  • With extended treatment, 92% of patients reached full resolution.

  • Statistical analysis confirmed a 1 in 555 quadrillion chance the results were due to placebo or random effect.

  • All participants experienced symptomatic improvement—many for the first time.

  • Zero reported adverse reactions.

Read the published study →

Microbes & Toxins Targeted by Inducen-LD/RF

Inducen-LD/RF was formulated to target infections and coinfections commonly seen in individuals with Lyme disease or relapsing fever. The electromagnetic sequences in this formula aim to induce or enhance native phage activity against the following:

Borrelia (Lyme species):
Includes Borrelia burgdorferi, afzelii, hermsii, miyamotoi, recurrentis, turicatae, and many others.

Bartonella (Cat Scratch & Coinfection strains):
Includes B. henselae, quintana, bacilliformis, koehlerae, and more.

Babesia (Malaria-like pathogens):
Includes B. microti, duncani, bovis, canis, gibsoni, etc.

Viral, Parasitic & Environmental Targets:

  • HHV-6, HHV-7, HHV-8

  • EBV, CMV, HPV

  • H1N1, H5N1

  • Retroviruses & Mixed Mycoplasma

  • Spike protein, Graphene oxide

  • Protomyxzoa rheumatica (FL1953)

  • Trypanosoma gambiense

  • Schistosoma mansoni

  • Rickettsia rickettsii

  • Tick-borne encephalitis virus

  • Ehrlichia spp.

  • Francisella tularensis

  • Leptospirosis

  • Mixed Plasmodium

  • LPS, endotoxins, and exotoxins

A full list of all 100+ targeted pathogens is available upon request or in the product documentation.

Clinical Guidance

This product is intended exclusively for use under the supervision of licensed health professionals. Dosage and treatment protocols should be tailored to each patient’s unique case history, concurrent therapies, and response.

Recommended Use:
1 ampule by mouth, twice daily.
Important Notes:
If patient is pregnant or breastfeeding, consult with a qualified healthcare practitioner prior to use.

For Practitioners Only

This page is provided for educational and ordering purposes exclusively to licensed medical professionals.

The Inducen formulations are not intended for direct-to-consumer sales, and are not evaluated by the FDA to diagnose, treat, cure, or prevent disease. PhagenCorp products are developed to support practitioners in providing precision adjunctive care within an integrative or bioregulatory framework.